{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:49:27Z","timestamp":1771210167345,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41409-025-02700-4","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T10:52:52Z","timestamp":1755773572000},"page":"1529-1532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesis"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6326-9283","authenticated-orcid":false,"given":"Paul","family":"Chauvet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Saade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Demaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-828X","authenticated-orcid":false,"given":"David","family":"Beauvais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-4187","authenticated-orcid":false,"given":"Micha","family":"Srour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Coiteux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Gazeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Branche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Roche-Lestienne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laur\u00e8ne","family":"Fenwarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4689-3882","authenticated-orcid":false,"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"2700_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber EW, Lynn RC, Sotillo E, Lattin J, Xu P, Mackall CL. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 2019;3:711\u20137.","journal-title":"Blood Adv"},{"key":"2700_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","volume":"11","author":"K Mestermann","year":"2019","unstructured":"Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR-T cells. Sci Transl Med. 2019;11:eaau5907.","journal-title":"Sci Transl Med"},{"key":"2700_CR3","doi-asserted-by":"publisher","first-page":"e005956","DOI":"10.1136\/jitc-2022-005956","volume":"10","author":"K Baur","year":"2022","unstructured":"Baur K, Heim D, Beerlage A, Poerings AS, Kopp B, Medinger M, et al. Dasatinib for treatment of CAR T-cell therapy-related complications. J Immunother Cancer. 2022;10:e005956.","journal-title":"J Immunother Cancer"},{"key":"2700_CR4","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gr\u00f6ger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988\u20131005.","journal-title":"Leukemia"},{"key":"2700_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3324\/haematol.2022.281351","volume":"108","author":"L Falini","year":"2023","unstructured":"Falini L, Venanzi A, Tini V, Innocente A, Ballanti S, Saldi S, et al. Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis. Haematologica. 2023;108:290\u20134.","journal-title":"Haematologica"},{"key":"2700_CR6","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41375-025-02605-7","volume":"39","author":"N Gazeau","year":"2025","unstructured":"Gazeau N, Beauvais D, Tilmont R, Srour M, Ferrant E, Safar V, et al. Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time? Leukemia. 2025;39:1714\u201322.","journal-title":"Leukemia"},{"key":"2700_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70160","volume":"9","author":"M Carlsten","year":"2025","unstructured":"Carlsten M, Lindfors Rossi EL, J\u00e4dersten M, Tesi B, Abd Own S, Sander B, et al. Development of myeloid neoplasia associated with prolonged immune cell\u2010associated hematotoxicity after CAR T\u2010cell treatment of B\u2010cell lymphoma: Should we surveille for pre\u2010existing myeloid mutations? HemaSphere. 2025;9:e70160.","journal-title":"HemaSphere"},{"key":"2700_CR8","doi-asserted-by":"publisher","first-page":"1000996","DOI":"10.3389\/fimmu.2022.1000996","volume":"13","author":"M Luciano","year":"2022","unstructured":"Luciano M, Krenn PW, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia. Front Immunol. 2022;13:1000996.","journal-title":"Front Immunol"},{"key":"2700_CR9","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18:3204\u201318.","journal-title":"Cell Rep"},{"key":"2700_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00536-x","volume":"11","author":"N Chen","year":"2021","unstructured":"Chen N, Xu Y, Mou J, Rao Q, Xing H, Tian Z, et al. Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood Cancer J. 2021;11:1\u201311.","journal-title":"Blood Cancer J"},{"key":"2700_CR11","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1159\/000541256","volume":"17","author":"F Volery","year":"2024","unstructured":"Volery F, Banz Y, Heini A, Kronig MN, Siegrist D, Daskalakis M, et al. Therapy-related acute myeloid leukemia after CAR-T cell therapy with brexucabtagene autoleucel for mantle cell lymphoma. Case Rep. Oncol. 2024;17:1087\u201393.","journal-title":"Case Rep. Oncol"},{"key":"2700_CR12","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138:2499\u2013513.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02700-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02700-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02700-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:20:13Z","timestamp":1762183213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02700-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2700"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02700-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PC: no conflict of interest related to this study. CS: no conflict of interest related to this study. JD: no conflict of interest related to this study. DB: no conflict of interest related to this study. LM: no conflict of interest related to this study. MS: no conflict of interest related to this study. VC: no conflict of interest related to this study. NG: no conflict of interest related to this study. NB: no conflict of interest related to this study. CRL: no conflict of interest related to this study. LF: no conflict of interest related to this study. EF: no conflict of interest related to this study. GD: no conflict of interest related to this study. IY-A: received honorarium from Gikead\/Kite, BMS, Novartis and AstraZeneca.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All analysis presented here were performed in accordance with the relevant guidelines and regulations. All participants provided written informed consent under ethics committee-approved biobank protocol \u201cCAR-LILLE\u201d(CPP ID-RCB: 2020-A01935-34) in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}